Download MendeleyStructural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain.
Kallen, J., Welzenbach, K., Ramage, P., Geyl, D., Kriwacki, R., Legge, G., Cottens, S., Weitz-Schmidt, G., Hommel, U.(1999) J Mol Biol 292: 1-9
- PubMed: 10493852
- DOI: https://doi.org/10.1006/jmbi.1999.3047
- Primary Citation of Related Structures:
1CQP - PubMed Abstract:
The lymphocyte function-associated antigen (LFA-1) belongs to the family of beta2-integrins and plays an important role in T-cell activation and leukocyte migration to sites of inflammation. We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1. Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain. The first three-dimensional structure of an integrin inhibitor bound to its receptor reveals atomic details for a hitherto unknown mode of LFA-1 inhibition. It also sheds light into possible mechanisms of LFA-1 mediated signalling and will support the design of novel anti-adhesive and immunosuppressive drugs.
Organizational Affiliation:
Preclinical Research, NOVARTIS PHARMA AG, Basel, CH 4002, Switzerland.
